Galderma Group AG SIX:GALD:
RECEIVES FDA COMPLETE RESPONSE LETTER FOR RELABOTULINUMTOXINA
FDA IDENTIFIES NO SAFETY OR EFFICACY DEFICIENCIES IN RELABOTULINUMTOXINA BLA
REGULATORY FILINGS FOR RELABOTULINUMTOXINA ONGOING AND ON TRACK IN OTHER TERRITORIES
TO SEEK FURTHER GUIDANCE FROM FDA TO RESOLVE OBSERVATIONS